Showing results (21-30 of 217) with videos related to

Sort By:
Pageof 22
Expert Opinion on Pharmacotherapy|December 1, 2005
Docetaxel in ovarian cancerPedro F Escobar, Peter G Rose
Gynecologic Oncology Reports|September 8, 2025
The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case seriesAndreea I Dinicu, Peter G Rose
International Journal of Nanomedicine|August 28, 2007
Pegylated liposomal doxorubicin in ovarian cancerAndrew E Green, Peter G Rose
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2007
Role of surgery in ovarian carcinomaAmanda Nickles Fader, Peter G Rose
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 13, 2009
Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxelAmanda N Fader, Peter G Rose
Anti-Cancer Drugs|May 26, 2017
Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancerAdam Pendlebury, Robert DeBernardo, Peter G Rose
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 20, 2015
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapyHaider Mahdi, Anthony Rizzo, Peter G Rose
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 12, 2014
Desensitization with oxaliplatin in patients intolerant of carboplatin desensitizationPeter G Rose, Carol Metz, Nicolas Link
Anti-Cancer Drugs|April 12, 2019
Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosingPeter G Rose, Denise Purpura, Lisa Petersen
Pageof 22